Recent Updates
Recently added Catalysts
ARWR Positive Sentiment

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

Monday, November 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arrowhead Pharmaceuticals will present key clinical data at the American Heart Association Scientific Sessions 2026. The presentation is scheduled for November 7, focusing on a first-in-human trial of a dual functional RNAi molecule. This event highlights advancements in lipid-lowering therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Arrowhead Pharmaceuticals will present important clinical data.
  • The presentation is at a prestigious event, AHA 2026.
  • The session focuses on novel lipid-lowering therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+4%
120-day peak, hindsight
Typical move
2%
average across 5 past catalysts
Cash runway
~24 mo
Minimal dilution risk
Lead asset
Plozasiran
Phase 3 · Severe Hypertriglyceridemia

Full Press Release Details

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week’s American Heart Association Scientific Sessions in Chicago. AHA 2026 Oral Presentations Date & Time: Saturday, November 7, 3:15 – 4:30 pm CT Session Title: FS.05: Featured Science Session on Novel Lipid Lowering Therapies Location: Learning Studio 2‚ Science and Technology Hall‚ South Hall Title: First-in-Human Trial of a Dual Functional RNAi Mo

Frequently Asked Questions

When will Arrowhead present its clinical data?

Arrowhead will present on November 7 at AHA 2026.

What is the focus of Arrowhead's presentation?

The presentation focuses on novel lipid-lowering therapies.

Where is the AHA 2026 event taking place?

The event is in Chicago, at the Science and Technology Hall.

What type of trial will Arrowhead discuss?

Arrowhead will discuss a first-in-human trial of a dual functional RNAi molecule.

ShareAdd on Google
Tags: ARWR Arrowhead Pharmaceuticals AHA 2026 clinical data lipid lowering therapies RNAi
Last updated: Nov 2, 2026

Biotech snapshot

Cash runway
$1602M liquidity · $59M/mo burn
~24 mo
Minimal dilution risk
Lead asset
PlozasiranPhase 3
Severe Hypertriglyceridemia →

Catalyst track record

+4%
best trade around ARWR's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ARWR.

See every catalyst's timing & PoA →